U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K/A
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 20, 2016
 
HH BIOTECHNOLOGY HOLDINGS COMPANY
(Exact name of registrant as specified in its charter)
 
0-23015
(Commission File No.)
 
Nevada
(State or other jurisdiction of
incorporation or organization)
87-0450232
(IRS Employer Identification No.)
 
C Site 25-26F President Building, No. 69 Heping North Street
Heping District, Shenyang 110003, Peoples Republic of China
(Address of principal executive offices)
 
0086-24-22813888
(Registrant’s telephone number)
 
Not applicable
(Former Name or Former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐    
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
Charles Mathews resigned as a director effective December 20, 2016, for personal reasons.
 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
HH Biotechnology Holdings Company
 
 
 
 
 
Date: December 26, 2016
By:  
/s/  Sheng Jiang
 
 
 
Sheng Jiang 
 
 
 
Chief Executive Officer